Literature DB >> 11244216

Synaptosomal proteins, beta-soluble N-ethylmaleimide-sensitive factor attachment protein (beta-SNAP), gamma-SNAP and synaptotagmin I in brain of patients with Down syndrome and Alzheimer's disease.

B C Yoo1, N Cairns, M Fountoulakis, G Lubec.   

Abstract

Although it is well-known that synaptosomal proteins are deranged in neurodegenerative disorders, no information is available at the protein-chemical level as mainly immunochemical or immunohistochemical data were reported previously. We therefore investigated synaptosomal proteins in brain specimens from patients with Down syndrome (DS) and Alzheimer's disease (AD) to challenge the DS synaptic pathology as well as the relevance of DS to AD in synaptic pathology. For the aim of this study, we employed two-dimensional electrophoresis and matrix-associated laser desorption ionization mass spectroscopy and determined beta-soluble N-ethylmaleimide-sensitive factor attachment protein (beta-SNAP), gamma-SNAP and synaptotagmin I (SYT I) in 7 individual brain regions of controls and patients with DS and AD. In DS brain, beta-SNAP was significantly reduced in temporal cortex (p < 0.01). SYT I (p65) and SYT I (pI 7.0) were significantly reduced in thalamus (p < 0.01 and p < 0.05, respectively). In AD brain, beta-SNAP was significantly decreased in temporal cortex (p < 0.05). SYT I (p65) was significantly reduced in cerebellum (p < 0.05), and temporal (p < 0.001) and parietal cortex (p < 0.01). SYT I (pI 7.0) was significantly reduced in temporal (p < 0.001) and parietal cortex (p < 0.01) and thalamus (p < 0.01). gamma-SNAP did not show any change in both DS and AD. The findings may explain impaired synaptogenesis in DS and AD brain, which is well documented in DS brain already early in life, and/or synaptosomal loss secondary to neuronal loss observed in both neurodegenerative disorders. It may also represent, reflect or account for the impaired neuronal transmission in DS and AD, caused by deterioration of the exocytic machinery. Here, we provide evidence for several deranged synaptosomal proteins in several brain regions at the protein level indicating deficient synaptosomal wiring of the brain in DS and AD. Copyright 2001 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11244216     DOI: 10.1159/000051261

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  14 in total

Review 1.  Genetics, transcriptomics, and proteomics of Alzheimer's disease.

Authors:  Andreas Papassotiropoulos; Michael Fountoulakis; Travis Dunckley; Dietrich A Stephan; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

Review 2.  Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.

Authors:  Donovan A McGrowder; Fabian Miller; Kurt Vaz; Chukwuemeka Nwokocha; Cameil Wilson-Clarke; Melisa Anderson-Cross; Jabari Brown; Lennox Anderson-Jackson; Lowen Williams; Lyndon Latore; Rory Thompson; Ruby Alexander-Lindo
Journal:  Brain Sci       Date:  2021-02-10

3.  First evidence of overlaps between HIV-Associated Dementia (HAD) and non-viral neurodegenerative diseases: proteomic analysis of the frontal cortex from HIV+ patients with and without dementia.

Authors:  Li Zhou; Eve Diefenbach; Ben Crossett; Sieu L Tran; Thomas Ng; Helen Rizos; Rejane Rua; Bin Wang; Amit Kapur; Kaushal Gandhi; Bruce J Brew; Nitin K Saksena
Journal:  Mol Neurodegener       Date:  2010-06-24       Impact factor: 14.195

4.  Identification of differentially expressed microRNAs and their target genes in the hippocampal tissues of Fmr1 knockout mice.

Authors:  Malan Zhang; Xin Li; Du Xiao; Tao Lu; Bing Qin; Zhigang Zheng; Yonggen Zhang; Yi Liu; Tiebin Yan; Xinjia Han
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

5.  Identification of Conserved Proteomic Networks in Neurodegenerative Dementia.

Authors:  Vivek Swarup; Timothy S Chang; Duc M Duong; Eric B Dammer; Jingting Dai; James J Lah; Erik C B Johnson; Nicholas T Seyfried; Allan I Levey; Daniel H Geschwind
Journal:  Cell Rep       Date:  2020-06-23       Impact factor: 9.423

6.  The effects of endogenous non-peptide molecule isatin and hydrogen peroxide on proteomic profiling of rat brain amyloid-β binding proteins: relevance to Alzheimer's disease?

Authors:  Alexei E Medvedev; Olga A Buneeva; Arthur T Kopylov; Oksana V Gnedenko; Marina V Medvedeva; Sergey A Kozin; Alexis S Ivanov; Victor G Zgoda; Alexander A Makarov
Journal:  Int J Mol Sci       Date:  2014-12-29       Impact factor: 5.923

7.  Vortioxetine administration attenuates cognitive and synaptic deficits in 5×FAD mice.

Authors:  Li-Xin Jiang; Geng-Di Huang; Feng Su; Huali Wang; Chen Zhang; Xin Yu
Journal:  Psychopharmacology (Berl)       Date:  2020-01-18       Impact factor: 4.530

8.  Broad Influence of Mutant Ataxin-3 on the Proteome of the Adult Brain, Young Neurons, and Axons Reveals Central Molecular Processes and Biomarkers in SCA3/MJD Using Knock-In Mouse Model.

Authors:  Kalina Wiatr; Łukasz Marczak; Jean-Baptiste Pérot; Emmanuel Brouillet; Julien Flament; Maciej Figiel
Journal:  Front Mol Neurosci       Date:  2021-06-17       Impact factor: 5.639

9.  Pleiotropic effects in Eya3 knockout mice.

Authors:  Torben Söker; Claudia Dalke; Oliver Puk; Thomas Floss; Lore Becker; Ines Bolle; Jack Favor; Wolfgang Hans; Sabine M Hölter; Marion Horsch; Magdalena Kallnik; Eva Kling; Corinna Moerth; Anja Schrewe; Christian Stigloher; Stefanie Topp; Valerie Gailus-Durner; Beatrix Naton; Johannes Beckers; Helmut Fuchs; Boris Ivandic; Thomas Klopstock; Holger Schulz; Eckhard Wolf; Wolfgang Wurst; Laure Bally-Cuif; Martin Hrabé de Angelis; Jochen Graw
Journal:  BMC Dev Biol       Date:  2008-12-22       Impact factor: 1.978

10.  Brief Communication: Maternal Plasma Autoantibodies Screening in Fetal Down Syndrome.

Authors:  Karol Charkiewicz; Monika Zbucka-Kretowska; Joanna Goscik; Slawomir Wolczynski; Adam Lemancewicz; Piotr Laudanski
Journal:  J Immunol Res       Date:  2016-03-06       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.